{"denoms":[{"counts":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"116"}],"units":"Participants"}],"groups":[{"description":"Patients receive 10, 15, 20, 30 or 40 mg/day panobinostat PO 3 times/week or on days 1, 3, 5, 15, 17, and 19 and 5 or 10 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Phase I (Panobinostat + Everolimus)"},{"description":"Patients receive 20,30, or 40 mg/day panobinostat PO on days 1, 3, 5, 15, 17, and 19 and 5 mg/day everolimus PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"Phase II (Panobinostat + Everolimus)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"24.0","upperLimit":"73.0","value":"61.0"},{"groupId":"BG001","lowerLimit":"20.0","upperLimit":"84.0","value":"59.0"},{"groupId":"BG002","lowerLimit":"20.0","upperLimit":"84.0","value":"59.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"34"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"82"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"93"},{"groupId":"BG002","value":"116"}]}],"title":"United States"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}]}